Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up
Phase of Trial: Phase III
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Ingenol disoxate (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 01 Sep 2017 Status changed from active, no longer recruiting to completed.
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 26 Jan 2016 New source identified and integrated (European Clinical Trials Database EudraCT2015-002452-27).